China's first pharmaceutical factory announced the realization of carbon neutralization: 8 years invested 7.5 million and saved 31 million

Economic Observation Network reporter Qu Yixian on August 19, Biophage Yingehan, a biopharmaceutical company, announced that it has obtained a limited The carbon neutralized certification issued by the company and the German Rhein TüV, which also represents the factory as the first carbon neutral factory in the Chinese pharmaceutical industry to obtain authoritative certification at home and abroad.

Yin Xuelin, general manager of Shanghai Bolin Ge Gelham Pharmaceutical Co., Ltd. told the Economic Observation Network that the front conditions of the carbon neutralization and certification are to buy green electricity, green rights and carbon credit.

Shanghai Zhangjiang Factory is one of the most important production centers in Bollinger Yinge Asia Pacific. After the carbon emission reached its peak in 2014, the factory has made a number of decreased designs in energy use, production and manufacturing process, and logistics management. 8 years have achieved zero carbon target.

From the perspective of value, compared with 2014, the factory reduced 12,103 tons of greenhouse gas emissions in 2021 (equivalent to carbon dioxide absorbed by about 45,000 trees in one year), and the energy consumption ratio per 100 million yuan decreased by 77%.

Yin Xuelin said that the factory has invested about 7.5 million yuan in energy -saving emission reductions in the past 8 years, and the energy fee that is directly saved is 31 million yuan. There is no need to increase investment in the future. Investment of 7.5 million yuan can continue to generate benefits. It can be further saved for the factory to save operating costs.

Generally speaking, the road of carbon in enterprises is divided into two steps: internal energy conservation and emission reduction, and green energy through carbon transactions and carbon credit.

Yin Xuelin introduced that the carbon neutralization of its factory is mainly realized from four aspects:

100%renewable power conversion, including laying solar photovoltaic boards on all roofs that can be used, and purchasing a videos of electric power in the solar power station located in Tianjin.

Energy efficiency improvement, including comprehensively adopting more energy -saving LED lighting systems, after partition, grouping, automatic lighting and other measures to improve the effectiveness of lighting; use built -in heat pumps and three -dimensional heat pipes to optimize production devices to make full use of the residual heat and residual pressure; Improve energy utilization efficiency and gradually eliminate refrigeration equipment with high global warming potential values ​​(GWP).

Carbon compensation (purchasing carbon credit), that is, through the channels recognized by Bolinger Yinghan Global Headquarters, invest and continue to follow up multiple environmental protection projects to help improve the survival status of inleaned areas, such as helping farmers in Sichuan to help farmers transform the stove and eventually transform into it into Carbon credit limit.

Green behavior, the concept of "green low -carbon" is advocated internally, and implemented in the daily behavior of employees, such as reduction of plastic reduction, priority natural light, green travel, green travel, etc.; The important conditions of the factory preferred suppliers to explore "green cooperation" with suppliers to achieve synergistic effects.

In Yin Xuelin's view, the production and manufacturing of drugs has GMP (drug production quality management specifications) requirements to ensure that the production environment of drugs requires a lot of energy consumption, so there are many things that the pharmaceutical industry can do in carbon neutrality.

Yin Xuelin told the Economic Observation Network that in the context of drug collection, more and more drugs will enter the collection. The problem of a significant decline in product prices is the problem of cost. Really reduce operating costs. In addition, in terms of scale, the scale of its factory is relatively small, with investment of 7.5 million yuan to save 31 million yuan. The space for large pharmaceutical factories in China can save much more than this.

He gave two examples in his own factory practice, such as drug research and development. The important task of the R & D center is to optimize the production process of the pharmaceutical front -end, which is equivalent to optimizing the synthesis path of compounds, such as shortening more than a dozen steps to three or four steps. The chemical reagents used in the process will decrease significantly. In addition, consider designing the use of vulnerable, explosive, and toxic and harmful compounds.

For another example, the medicines have medicine boxes. During the production process, the weight of the paper is reduced, using paper with a forest recovery certificate, and so on.

- END -